CL4-modified exosomes deliver lncRNA DARS-AS1 siRNA to suppress triple-negative breast cancer progression and attenuate doxorubicin resistance by inhibiting autophagy.

[1]  Shangyong Li,et al.  Co-delivery of doxorubicin and hydroxychloroquine via chitosan/alginate nanoparticles for blocking autophagy and enhancing chemotherapy in breast cancer therapy , 2023, Frontiers in Pharmacology.

[2]  K. Witwer,et al.  Extracellular vesicles: the next generation in gene therapy delivery. , 2023, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Jiujie Cui,et al.  Prediction of Survival and Tumor Microenvironment Infiltration Based on Pyroptosis-Related lncRNAs in Pancreatic Cancer , 2022, Disease markers.

[4]  Jordan J. Green,et al.  Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma , 2022, Science advances.

[5]  Xiangliang Yang,et al.  Extracellular‐Vesicle‐Based Drug Delivery Systems for Enhanced Antitumor Therapies through Modulating the Cancer‐Immunity Cycle , 2022, Advanced materials.

[6]  Gang Zhao,et al.  Exosomes deliver lncRNA DARS-AS1 siRNA to inhibit chronic unpredictable mild stress-induced TNBC metastasis. , 2022, Cancer letters.

[7]  Jeffrey T. Chang,et al.  Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  B. Han,et al.  Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies , 2022, Journal of Hematology & Oncology.

[9]  Xiaolu Yang,et al.  Autophagy and pluripotency: self-eating your way to eternal youth. , 2022, Trends in cell biology.

[10]  M. Shariati,et al.  Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives. , 2022, Seminars in cancer biology.

[11]  K. Wisinski,et al.  Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer , 2022, Cancers.

[12]  Zihua Zeng,et al.  Aptamer-armed nanostructures improve the chemotherapy outcome of triple-negative breast cancer. , 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Qiming Wang,et al.  DARS-AS1 recruits METTL3/METTL14 to bind and enhance DARS mRNA m6A modification and translation for cytoprotective autophagy in cervical cancer , 2022, RNA biology.

[14]  L. Gianni,et al.  Treatment landscape of triple-negative breast cancer — expanded options, evolving needs , 2021, Nature Reviews Clinical Oncology.

[15]  Hongjie Xiong,et al.  Engineered Aptamer-Organic Amphiphile Self-Assemblies for Biomedical Applications: Progress and Challenges. , 2021, Small.

[16]  D. Yin,et al.  miR-194-Loaded Gelatin Nanospheres Target MEF2C to Suppress Muscle Atrophy in a Mechanical Unloading Model. , 2021, Molecular pharmaceutics.

[17]  L. Cerchia,et al.  Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors , 2021, Journal of experimental & clinical cancer research : CR.

[18]  C. Maher,et al.  Long noncoding RNAs in cancer metastasis , 2021, Nature Reviews Cancer.

[19]  Fei Chen,et al.  Connections between endoplasmic reticulum stress-associated unfolded protein response, mitochondria, and autophagy in arsenic-induced carcinogenesis. , 2021, Seminars in cancer biology.

[20]  A. Dash,et al.  Liposomes and transferosomes: a breakthrough in topical and transdermal delivery. , 2021, Therapeutic delivery.

[21]  Shichao Han,et al.  Downregulation of LncRNA DARS-AS1 Inhibits the Tumorigenesis of Cervical Cancer via Inhibition of IGF2BP3 , 2021, OncoTargets and therapy.

[22]  Haocai Chang,et al.  Targeting autophagy to overcome drug resistance: further developments , 2020, Journal of Hematology & Oncology.

[23]  G. Sheng,et al.  Oncogenic Long Noncoding RNA DARS-AS1 in Childhood Acute Myeloid Leukemia by Binding to microRNA-425 , 2020, Technology in cancer research & treatment.

[24]  I. Berindan‐Neagoe,et al.  New perspectives in triple-negative breast cancer therapy based on treatments with TGFβ1 siRNA and doxorubicin , 2020, Molecular and Cellular Biochemistry.

[25]  M. Cantile,et al.  Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer , 2020, Journal of experimental & clinical cancer research : CR.

[26]  R. Keri,et al.  KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene , 2020, Breast Cancer Research.

[27]  Xiukun Lin,et al.  Exosomes-coated bcl-2 siRNA inhibits the growth of digestive system tumors both in vitro and in vivo. , 2020, International journal of biological macromolecules.

[28]  Hui Guo,et al.  DARS-AS1 promotes clear cell renal cell carcinoma by sequestering miR-194-5p to up-regulate DARS. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[29]  Dana A. Alqudah,et al.  Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes , 2020, Breast Cancer.

[30]  W. Zheng,et al.  LncRNA DARS-AS1 regulates microRNA-129 to promote malignant progression of thyroid cancer. , 2019, European review for medical and pharmacological sciences.

[31]  L. Jie,et al.  Recent treatment progress of triple negative breast cancer. , 2019, Progress in biophysics and molecular biology.

[32]  Jenifer R Prosperi,et al.  APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells , 2019, Neoplasia.

[33]  Sajjad Karim,et al.  Nanoparticles-based drug delivery and gene therapy for breast cancer: recent advancements and future challenges. , 2019, Seminars in cancer biology.

[34]  W. Duan,et al.  Exosomes and Nanoengineering: A Match Made for Precision Therapeutics , 2019, Advanced materials.

[35]  Wei Tao,et al.  ROS‐Responsive Polymeric siRNA Nanomedicine Stabilized by Triple Interactions for the Robust Glioblastoma Combinational RNAi Therapy , 2019, Advanced materials.

[36]  Haibo Liu,et al.  Long non-coding RNA DARS-AS1 promotes tumorigenesis of non-small cell lung cancer via targeting miR-532-3p. , 2019, Minerva medica.

[37]  F. Zhan,et al.  Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy , 2019, Haematologica.

[38]  Z. Gil,et al.  Exosomes and their role in tumorigenesis and anticancer drug resistance. , 2019, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[39]  E. Fattal,et al.  Aptamer‐guided nanomedicines for anticancer drug delivery , 2018, Advanced drug delivery reviews.

[40]  E. Crescenzi,et al.  Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications. , 2018, Biochimica et biophysica acta. Reviews on cancer.

[41]  E. Crescenzi,et al.  Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers , 2017, Scientific Reports.

[42]  Liuting Mo,et al.  Aptamer-integrated DNA nanostructures for biosensing, bioimaging and cancer therapy. , 2016, Chemical Society reviews.

[43]  Walhan Alshaer,et al.  Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells. , 2015, Bioconjugate chemistry.

[44]  Louai Labanieh,et al.  Nucleic acid aptamers in cancer research, diagnosis and therapy. , 2015, Chemical Society reviews.

[45]  T. Anchordoquy,et al.  Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[46]  J. Balko,et al.  TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. , 2013, The Journal of clinical investigation.

[47]  Hiroshi I. Suzuki,et al.  Autophagy is activated by TGF-beta and potentiates TGF-beta-mediated growth inhibition in human hepatocellular carcinoma cells. , 2009, Cancer research.

[48]  Wei He,et al.  Insight on Multidrug Resistance and Nanomedicine Approaches to Overcome MDR. , 2020, Critical reviews in therapeutic drug carrier systems.

[49]  Gong Cheng,et al.  Aptamer-Conjugated Extracellular Nanovesicles for Targeted Drug Delivery. , 2018, Cancer research.

[50]  W. Gradishar,et al.  Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. , 2017, Cancer treatment reviews.